| Peer-Reviewed

Assessment of Healthcare Providers Compliance with Standard of MDR TB Care and Treatment Outcome

Received: 19 July 2021    Accepted: 28 July 2021    Published: 4 August 2021
Views:       Downloads:
Abstract

The acquisition of MDR-TB results mainly from health system/service and patient-related factors. Previous studies showed that factors that affect health outcome can be human (patient, healthcare provider) and health system related. Poor quality of care provided to TB patients affects treatment outcome which could trigger development and spread of multidrug resistant TB. This study was conducted to assess treatment outcome of Multidrug resistant clients in Drug Resistant TB treatment centers in North Central Nigeria and assess also compliance of healthcare provider with the standard of MDR TB care and services they render. Data of 300 MDR TB clients were retrospectively collected after a review of the register and drug charts. Twenty-seven (27) participants were selected at random from the 3 states TB program and 18 health facility staff were also selected to answer questions related to compliance of facility and healthcare providers with MDR TB care/services. Response with scores zero (0) and 50% were seen as areas where compliance with the standard was lacking. Identification, training, supervision, and compensation for community treatment supporters, infection control, Socioeconomic and psychological support (including incentives, enablers), expert committee to routinely provide clinical/programmatic consultation prompt treatment initiation, use of electronic drug management system, support groups, adherence to standard operating procedures at facilities. The treatment outcome documented in the study were cured (61.7%), completed treatment (7.3%), still on treatment (17.7%), defaulted (1.3%), failed treatment (0.7%), Pre-XDR TB (4.7%), lost to follow up (1.3%), transferred out (0.7%) and died (9.7%). The study disclosed the treatment outcome of MDR TB clients and areas that compliance with standard is lacking. There is need for TB programmers to periodically assess their services and clients for continuous improvement of the program.

Published in World Journal of Public Health (Volume 6, Issue 3)
DOI 10.11648/j.wjph.20210603.12
Page(s) 81-88
Creative Commons

This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.

Copyright

Copyright © The Author(s), 2024. Published by Science Publishing Group

Keywords

Assessment of Healthcare Providers, Compliance, Predictor of Treatment Failure, Treatment Outcome, MDR TB, Nigeria

References
[1] World Health Organization (2012). Global tuberculosis report 2012. WHO/HTM/TB/2012.6.
[2] Oyediran, K. (2019). Quality of Tuberculosis Services Assessment in Nigeria: Report. Chapel Hill, NC, USA: MEASURE Evaluation, University of North Carolina.
[3] Royce Sarah, Islam Tauhid, Jakubowiak Wieslaw, Jaramillo Ernesto, Ines Garcia Baena, D’Arcy Richardson, Lisa Mueller, Lesley Reed, and Katherine Doyle (2012). PATH’s MDR TB Planning Toolkit. MDR TB Essential Element Reference list. Pages 29-34. https://path.azureedge.net/media/documents/TB_mdr-tb_toolkit.pdf
[4] Bouchet B. Monitoring the Quality of Primary Care: Health Manager’s Guide. Bethesda, MD: Quality Assurance Project. Undated.
[5] Institute of Medicine. (1999). To err is human: building a safer health system. Washington, DC: National Academy Press.
[6] Olanrewaju Oladimeji, Daniel Adedayo Adeyinka, Lehlogonolo Makola, Kabwebwe Honoré Mitonga, Ekerette Emmanuel Udoh, Boniface Ayanbekongshie Ushie, Kelechi Elizabeth Oladimeji, Jeremiah Chikovore, Musawenkosi Mabaso, Atilola Adeleke, Osman Eltayeb, Oluwatoyin J. Kuye, Gidado Mustapha, Olusoji Mayowa Ige, Joyce Nonhlanhla Mbatha, Jacob Creswell, Joyce M. Tsoka-Gwegweni, Lovett Lawson and Ehimario Uche Igumbor. (2018). Clients’ Perception of Quality of Multidrug-Resistant Tuberculosis Treatment and Care in Resource-Limited Setting: Experience from Nigeria. Intechopen: Research and development. 10: 190-206. http://dx.doi.org/10.5772/intechopen.76001.
[7] Liang, L., Wu, Q., Gao, L., Hao, Y., Liu, C., Xie, Y., Sun, H., Yan, X., Li, F., Li, H., Fang, H., Ning, N., Cui, Y., & Han, L. (2012). Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. Thorax, 67, 632-638.
[8] Uzoewulu NG, Ibeh IN, Lawson L, Goyal M, Umenyonu N, et al. (2014) Drug Resistant Mycobacterium tuberculosis in Tertiary HospitalSouth East, Nigeria. J Med Microb Diagn 3: 141. doi: 10.4172/2161-0703.1000141.
[9] Mekonnen F., Tessema B., Moges F., Gelaw A., Eshetie S., and Kumera G.,(2015). “Multidrug resistant tuberculosis: prevalence and risk factors in districts of Metema and West Armachiho, Northwest Ethiopia,” BMC Infectious Diseases, vol. 15, no. 1, p. 461.
[10] Mehari, K., Asmelash, T., Hailekiros, H., Wubayehu, T., Godefay, H., Araya, T., & Saravanan, M. (2019). Prevalence and Factors Associated with Multidrug-Resistant Tuberculosis (MDR-TB) among Presumptive MDR-TB Patients in Tigray Region, Northern Ethiopia. The Canadian Journal of Infectious Diseases & Medical Microbiology=Journal Canadien des Maladies Infectieuses et de la Microbiologie Médicale.
[11] Chavez Pachas AM, Blank R, Smith Fawzi MC, Bayona J, Becerra MC and Mitnick CD. (2004). Identifying early treatment failure on category Itherapy for pulmonary tuberculosis in LimaCiudad, Peru. Int J Tuberc Lung Dis. 8: 52-58.
[12] Namukwaya, Elizabeth & Nakwagala, F & Mulekya, F & Mayanja-Kizza, Harriet & Mugerwa, R. (2011). Predictors of treatment failure among pulmonary tuberculosis patients in Mulago hospital, Uganda. African health sciences. 11 Suppl 1. S105-11. 10.4314/ahs.v11i3.70079.
[13] Mamo, Ayele & Mama, Mohammedaman & Solomon, Damtew & Hassen, Mesud. (2021). Treatment Outcomes and Predictors Among Tuberculosis Patients at Madda Walabu University Goba Referral Hospital, Southeast Ethiopia. Infection and Drug Resistance. Volume 13. 4763-4771. 10.2147/IDR.S285542.
[14] Babatunde O. A., Elegbede O. E., Ayodele M, Fadare J. O., Isinjaye A. O., Ibirongbe D. O., and Akinyandenu J. (2013). Factors Affecting Treatment Outcomes of Tuberculosis in a Tertiary Health Center in Southwestern Nigeria. International Review of Social Sciences and Humanities Vol. 4, No. 2 (2013), pp. 209-218.
[15] Ajema, D., Shibru, T., Endalew, T. et al. (2020). Level of and associated factors for non-adherence to anti-tuberculosis treatment among tuberculosis patients in Gamo Gofa zone, southern Ethiopia: cross-sectional study. BMC Public Health 20, 1705. https://doi.org/10.1186/s12889-020-09827-7
[16] Oladimeji O, Adepoju V, Anyiam FE, San JE, Odugbemi BA, Hyera FLM, et al. (2021). Treatment outcomes of drug susceptible Tuberculosis in private health facilities in Lagos, South-West Nigeria. PLoS ONE 16 (1): e0244581. https://doi.org/10.1371/journal.pone.024458
[17] Federal Ministry of Health. (2008). Guidelines For Clinical Management of Tb and Hiv/Aids Related Conditions In Nigeria. Pp 7. https://www.who.int/hiv/pub/guidelines/nigeria.pdf
[18] Adebisi Y A, Agumage I, Sylvanus T D, Nawaila I J, Ekwere W A, et al. Burden of Tuberculosis and Challenges Facing Its Eradication in West Africa, Int J Infect. Online ahead of Print; 6 (3): e92250. doi: 10.5812/iji.92250.
[19] World Health Organization (2019). Multidrug Resistant Tuberculosis 2018 Update. https://www.who.int/tb/areas-of-work/drug-resistant-tb/MDR-RR_TB_factsheet_2018_Apr2019.pdf
[20] Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D. (2014). Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis. 15; 59 (10): 1364-74. doi: 10.1093/cid/ciu619. PMID: 25097082; PMCID: PMC4296130.
[21] Seung, K. J., Keshavjee, S., & Rich, M. L. (2015). Multidrug-Resistant Tuberculosis and Extensively Drug-Resistant Tuberculosis. Cold Spring Harbor perspectives in medicine, 5 (9), a017863. https://doi.org/10.1101/cshperspect.a017863
[22] Tola, H. H., Tol, A., Shojaeizadeh, D., & Garmaroudi, G. (2015). Tuberculosis Treatment Non-Adherence and Lost to Follow Up among TB Patients with or without HIV in Developing Countries: A Systematic Review. Iranian journal of public health, 44 (1), 1–11.
[23] Christoph Lange, Ibrahim Abubakar, Jan-Willem C. Alffenaar, Graham Bothamley, Jose A. Caminero, Anna Cristina C. Carvalho, Kwok-Chiu Chang, Luigi Codecasa, Ana Correia, Valeriu Crudu, Peter Davies, Martin Dedicoat, Francis Drobniewski, Raquel Duarte, Cordula Ehlers, Connie Erkens, Delia Goletti, Gunar Günther, Elmira Ibraim, Beate Kampmann, Liga Kuksa, Wiel de Lange, Frank van Leth, Jan van Lunzen, Alberto Matteelli, Dick Menzies, Ignacio Monedero, Elvira Richter, Sabine Rüsch-Gerdes, Andreas Sandgren, Anna Scardigli, Alena Skrahina, Enrico Tortoli, Grigory Volchenkov, Dirk Wagner, Marieke J. van der Werf, Bhanu Williams, Wing-Wai Yew, Jean-Pierre Zellweger, Daniela Maria Cirillo for the TBNET. (2014). European Respiratory Journal, 44: 23-63; DOI: 10.1183/09031936.00188313.
[24] Thomas E Herchline, Michael Stuart Bronze, Judith K Amorosa (2020). Which factors contribute to the high prevalence of multidrug resistant tuberculosis (MDR-TB)?
[25] Hughes RG. (2008). Tools and Strategies for Quality Improvement and Patient Safety. In: Hughes RG, editor. Patient Safety and Quality: An Evidence-Based Handbook for Nurses. Rockville (MD): Agency for Healthcare Research and Quality (US); Chapter 44. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2682/
[26] Tembo BP and Malangu NG. (2019). Prevalence and factors associated with multidrug/rifampicin resistant tuberculosis among suspected drug resistant tuberculosis patients in Botswana. BMC Infect Dis. 6; 19 (1): 779. doi: 10.1186/s12879-019-4375-7. PMID: 31492099; PMCID: PMC6728949.
Cite This Article
  • APA Style

    Laura Madukaji, Ebenezer Obi Daniel, Francis Ejeh, Adewole Olanisun Olufemi, Ahmed Mamuda Bello, et al. (2021). Assessment of Healthcare Providers Compliance with Standard of MDR TB Care and Treatment Outcome. World Journal of Public Health, 6(3), 81-88. https://doi.org/10.11648/j.wjph.20210603.12

    Copy | Download

    ACS Style

    Laura Madukaji; Ebenezer Obi Daniel; Francis Ejeh; Adewole Olanisun Olufemi; Ahmed Mamuda Bello, et al. Assessment of Healthcare Providers Compliance with Standard of MDR TB Care and Treatment Outcome. World J. Public Health 2021, 6(3), 81-88. doi: 10.11648/j.wjph.20210603.12

    Copy | Download

    AMA Style

    Laura Madukaji, Ebenezer Obi Daniel, Francis Ejeh, Adewole Olanisun Olufemi, Ahmed Mamuda Bello, et al. Assessment of Healthcare Providers Compliance with Standard of MDR TB Care and Treatment Outcome. World J Public Health. 2021;6(3):81-88. doi: 10.11648/j.wjph.20210603.12

    Copy | Download

  • @article{10.11648/j.wjph.20210603.12,
      author = {Laura Madukaji and Ebenezer Obi Daniel and Francis Ejeh and Adewole Olanisun Olufemi and Ahmed Mamuda Bello and Paul Olaiya Abiodun and Israel Olukayode Popoola and Kabir Yunusa Amar and Christiana Asibi Ogben and Michael Oladapo Olagbegi and Gabriel Omoniyi Ayeni and Olayinka Victor Ojo and John Danjuma Mawak},
      title = {Assessment of Healthcare Providers Compliance with Standard of MDR TB Care and Treatment Outcome},
      journal = {World Journal of Public Health},
      volume = {6},
      number = {3},
      pages = {81-88},
      doi = {10.11648/j.wjph.20210603.12},
      url = {https://doi.org/10.11648/j.wjph.20210603.12},
      eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.wjph.20210603.12},
      abstract = {The acquisition of MDR-TB results mainly from health system/service and patient-related factors. Previous studies showed that factors that affect health outcome can be human (patient, healthcare provider) and health system related. Poor quality of care provided to TB patients affects treatment outcome which could trigger development and spread of multidrug resistant TB. This study was conducted to assess treatment outcome of Multidrug resistant clients in Drug Resistant TB treatment centers in North Central Nigeria and assess also compliance of healthcare provider with the standard of MDR TB care and services they render. Data of 300 MDR TB clients were retrospectively collected after a review of the register and drug charts. Twenty-seven (27) participants were selected at random from the 3 states TB program and 18 health facility staff were also selected to answer questions related to compliance of facility and healthcare providers with MDR TB care/services. Response with scores zero (0) and 50% were seen as areas where compliance with the standard was lacking. Identification, training, supervision, and compensation for community treatment supporters, infection control, Socioeconomic and psychological support (including incentives, enablers), expert committee to routinely provide clinical/programmatic consultation prompt treatment initiation, use of electronic drug management system, support groups, adherence to standard operating procedures at facilities. The treatment outcome documented in the study were cured (61.7%), completed treatment (7.3%), still on treatment (17.7%), defaulted (1.3%), failed treatment (0.7%), Pre-XDR TB (4.7%), lost to follow up (1.3%), transferred out (0.7%) and died (9.7%). The study disclosed the treatment outcome of MDR TB clients and areas that compliance with standard is lacking. There is need for TB programmers to periodically assess their services and clients for continuous improvement of the program.},
     year = {2021}
    }
    

    Copy | Download

  • TY  - JOUR
    T1  - Assessment of Healthcare Providers Compliance with Standard of MDR TB Care and Treatment Outcome
    AU  - Laura Madukaji
    AU  - Ebenezer Obi Daniel
    AU  - Francis Ejeh
    AU  - Adewole Olanisun Olufemi
    AU  - Ahmed Mamuda Bello
    AU  - Paul Olaiya Abiodun
    AU  - Israel Olukayode Popoola
    AU  - Kabir Yunusa Amar
    AU  - Christiana Asibi Ogben
    AU  - Michael Oladapo Olagbegi
    AU  - Gabriel Omoniyi Ayeni
    AU  - Olayinka Victor Ojo
    AU  - John Danjuma Mawak
    Y1  - 2021/08/04
    PY  - 2021
    N1  - https://doi.org/10.11648/j.wjph.20210603.12
    DO  - 10.11648/j.wjph.20210603.12
    T2  - World Journal of Public Health
    JF  - World Journal of Public Health
    JO  - World Journal of Public Health
    SP  - 81
    EP  - 88
    PB  - Science Publishing Group
    SN  - 2637-6059
    UR  - https://doi.org/10.11648/j.wjph.20210603.12
    AB  - The acquisition of MDR-TB results mainly from health system/service and patient-related factors. Previous studies showed that factors that affect health outcome can be human (patient, healthcare provider) and health system related. Poor quality of care provided to TB patients affects treatment outcome which could trigger development and spread of multidrug resistant TB. This study was conducted to assess treatment outcome of Multidrug resistant clients in Drug Resistant TB treatment centers in North Central Nigeria and assess also compliance of healthcare provider with the standard of MDR TB care and services they render. Data of 300 MDR TB clients were retrospectively collected after a review of the register and drug charts. Twenty-seven (27) participants were selected at random from the 3 states TB program and 18 health facility staff were also selected to answer questions related to compliance of facility and healthcare providers with MDR TB care/services. Response with scores zero (0) and 50% were seen as areas where compliance with the standard was lacking. Identification, training, supervision, and compensation for community treatment supporters, infection control, Socioeconomic and psychological support (including incentives, enablers), expert committee to routinely provide clinical/programmatic consultation prompt treatment initiation, use of electronic drug management system, support groups, adherence to standard operating procedures at facilities. The treatment outcome documented in the study were cured (61.7%), completed treatment (7.3%), still on treatment (17.7%), defaulted (1.3%), failed treatment (0.7%), Pre-XDR TB (4.7%), lost to follow up (1.3%), transferred out (0.7%) and died (9.7%). The study disclosed the treatment outcome of MDR TB clients and areas that compliance with standard is lacking. There is need for TB programmers to periodically assess their services and clients for continuous improvement of the program.
    VL  - 6
    IS  - 3
    ER  - 

    Copy | Download

Author Information
  • Department of Public Health, Texila American University, Georgetown, Guyana

  • Department of Public Health, Texila American University, Georgetown, Guyana

  • Department of Veterinary Microbiology, Faculty of Veterinary Medicine, University of Maiduguri, Borno, Nigeria

  • Department of Medicine, Obafemi Awolowo University Ile-Ife, Ile Ife, Nigeria

  • Department of Public Health, Texila American University, Georgetown, Guyana

  • Department of Public Health, Texila American University, Georgetown, Guyana

  • Department of Epidemiology and Community Health, University of Ilorin, Ilorin, Nigeria

  • Department of Psychology, Benue State University, Makurdi, Nigeria

  • Department of Public Health, Texila American University, Georgetown, Guyana

  • South African National Bioinformatics Institute, University of the Western Cape, Western Cape, South Africa

  • Department of Public Health, Texila American University, Georgetown, Guyana

  • Department of Public Health, Texila American University, Georgetown, Guyana

  • Department of Microbiology, University of Jos, Plateau, Nigeria

  • Sections